Introduction
============

Human pterygium, a common ocular surface disease, is characterized by chronic proliferation of limbal epithelial cells and fibrovascular tissue, forming a wing-like shape, which obstructs the visual axis ([@b1-mmr-16-04-5285]). Pathobiology of this lesion includes various mechanisms, such as stem cell dysfunction, cellular proliferation and aberration of apoptosis, epithelial-mesenchymal transition, inflammatory influence, genetic instability, angiogenesis, redox related toxicity and hypoxia ([@b2-mmr-16-04-5285]--[@b4-mmr-16-04-5285]).

The cannabinoid receptor family includes cannabinoid receptor type 1 (CB1) and CB2, which belong to the seven transmembrane-spanning superfamily of G protein-coupled receptors and are the targets of naturally, synthetic or endogenous cannabinoid ligands. CB1 receptor has the highest expression level in the brain ([@b5-mmr-16-04-5285],[@b6-mmr-16-04-5285]) whereas CB2 receptor expression is predominantly found in the immune system (B lymphocyte enriched areas) ([@b7-mmr-16-04-5285]). The cannabinoid system modulates various physiological processes of the nervous and immune systems, and is key in cell proliferation, differentiation and survival ([@b6-mmr-16-04-5285],[@b8-mmr-16-04-5285],[@b9-mmr-16-04-5285]). Thus, cannabinoids have been reported as putative therapeutic agents for the treatment of neurodegenerative diseases, multiple sclerosis, glaucoma, neuropathic and inflammatory pain, as well as cancer ([@b10-mmr-16-04-5285]--[@b12-mmr-16-04-5285]). It has been discovered that members of the transient receptor potential (TRP) protein superfamily of cation channels are activated by cannabinoids ([@b13-mmr-16-04-5285]), whereas the two cannabinoid receptors and the TRP channels have more than one cannabinoid ligand ([@b14-mmr-16-04-5285]). TRP vanilloid (TRPV) channels belong to the TRP superfamily and are also activated by various stimuli ([@b15-mmr-16-04-5285]). Notably, TRPV1 was originally discovered as the pharmacological site of action of pungent vanilloid compounds, such as capsaicin. In addition, noxious heat (\>43°C) and high temperatures (\>52°C) activate TRPV1 and TRPV2, respectively. Warm temperatures in the range of 32--39°C activate TRPV3 and moderate heat (\>27°C) activates TRPV4. Furthermore, chemical stimuli that include diphenyl-containing compounds, which activate TRPV2, and plant-derived compounds, such as camphor, carvacol and incensole acetate, which activate TRPV3 ([@b16-mmr-16-04-5285]--[@b25-mmr-16-04-5285]). TRPV4 was originally identified as a channel that could be gated by changes in osmolarity ([@b26-mmr-16-04-5285]), but it also elicits responses to a variety of endogenous and exogenous agonists, such as the phytochemical, bisandrographolide A and the phorbol ester, 4α-phorbol 12,13-didecanoate, and the small molecule TRPV4 channel activator, GSK1016790A ([@b27-mmr-16-04-5285]--[@b29-mmr-16-04-5285]). Thus, TRP channels are important mediators of nociception, mechano-, osmo- and thermosensation, regulating cellular functions and signaling pathways ([@b13-mmr-16-04-5285]). Inherited (channelopathy) or acquired dysfunction of TRP channels has been implicated in various diseases, providing these channels as targets for many currently prescribed therapeutic agents ([@b30-mmr-16-04-5285]).

Growing evidence demonstrates that cannabinoid receptors and TRP channels are coexpressed in certain tissue samples suggesting that there is a functional interaction by which cannabinoids may regulate physiological processes. Yang *et al* ([@b31-mmr-16-04-5285]) reported that CB1 activation suppressed TRPV1-induced increases in interleukin (IL)-6 and IL-8 in corneal epithelial cells, implying a novel drug strategy to reduce TRPV1-induced proinflammatory cytokine release. Furthermore, as various cell types in synovial tissue express CB1 and TRPs, cannabinoid-based therapeutic agents targeting CB1 and TRPV1 have been proposed to reduce inflammation in rheumatoid arthritis ([@b32-mmr-16-04-5285],[@b33-mmr-16-04-5285]). Together with the above findings, CB1 activation has been shown to produce analgesia by preventing nerve growth factor-induced sensitization of TRPV1 in adult mouse afferent nociceptor nerve endings ([@b34-mmr-16-04-5285],[@b35-mmr-16-04-5285]). Finally, experimental data in the skin support a model in which cannabinoids indirectly suppress TRPV1 effects on pain and inflammation by acting at CB1, but directly activate TRPV1 at higher concentrations ([@b36-mmr-16-04-5285]). However, primarily with respect to nociceptive responses, the effect of CB1 on TRPV1 may not always be inhibitory ([@b37-mmr-16-04-5285]).

Human and rat conjunctiva demonstrate widespread tissue localization of cannabinoid receptors. It has been reported that conjunctival cannabinoid receptors are important in the regulation of epithelial renewal and inflammatory processes at the ocular surface ([@b38-mmr-16-04-5285]). Previously, TRPV1, TRPV2 and TRPV4 gene expression, and cellular localization was detected and functionally characterized, with regard to thermosensitivity and regulatory volume behavior, in human conjunctival epithelial cells and *ex vivo* human conjunctivas ([@b39-mmr-16-04-5285]). The aim of the present study was to investigate the distribution patterns of cannabinoid receptors (CB1 and CB2) and TRPV channels in the human conjunctival lesion, pterygium.

Materials and methods
=====================

### Patients

A total of 32 patients of Greek origin (22 males and 10 females; mean age, 72.5 years) with primary (n=27) or recurrent (n=5) pterygia, who underwent routine pterygium excision surgery at the Department of Ophthalmology, University Hospital of Patras (Rio, Greece) between January 2008 and February 2010, were included in the present study. Bulbar conjunctival tissues (n=8; mean age, 72 years) from patients undergoing glaucoma or cataract surgery were collected from the same department, during the same period. The use of the human specimens was in accordance with the University Hospital of Patras Ethics Commission. All research protocols were conducted and patients were treated in accordance with the tenets of the Declaration of Helsinki. Written informed consent was obtained from all patients.

### Immunohistochemistry

All tissues for immunohistochemistry were fixed in formalin and embedded in paraffin. Consecutive (semi-serial) 4-µm sections of ocular pterygium and normal conjunctival tissue samples were collected on poly-L-lysine-coated slides. Pterygia were oriented such that sections were cut longitudinally through the head and the body of the pterygium. One section for each sample was stained with hematoxylin and eosin. For immunohistochemical studies, the histological sections were deparaffinized in xylene and rehydrated through a graded series of alcohols to water. Antigen retrieval was performed by microwaving the slides in 0.01 M citrate buffer (pH 6). Endogenous peroxidase activity was quenched by treatment with 1% hydrogen peroxide for 20 min. Incubation at room temperature with 1% bovine serum albumin (SERVA, Heidelberg, Germany) in Tris-HCl-buffered saline was performed for 10 min. Sections were subsequently incubated with the following primary antibodies: Anti-CB1 (cat no. C2866; dilution, 1:100; Merck KGaA, Darmstadt, Germany) and anti-CB2 (cat no. 101550; dilution, 1:100; Cayman Chemical Co., Ann Arbor, MI, USA). In addition, a rabbit polyclonal antibody, phosphorylated-CB1 \[p-CB1 (Ser316)\], raised against a short amino acid sequence containing phosphorylated Ser316 of CB1 of human origin (cat no. sc-17555; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) was used. TRPV channel expression was detected using polyclonal rabbit anti-TRPV1 antibody (cat no. NBP1-71774; dilution, 1:200) manufactured by Novus Biologicals, Ltd. (Cambridge, UK), polyclonal rabbit anti-TRPV2 (cat no. TA317464; dilution 1:200) and monoclonal mouse anti-TRPV3 antibody (cat no. AM20072PU-N; dilution 1:300) produced by Acris Antibodies GmbH (Herford, Germany) and rabbit polyclonal anti-TRPV4 antibody from Abcam (cat no. ab39260; dilution 1:200 Cambridge, UK). Detection was performed using the EnVision Plus Detection System kit, according to the manufacturer\'s instructions (Dako Cytomation; Agilent Technologies, Inc., Santa Clara, CA, USA), with 3,3′-diaminobenzidine (DAB) as a chromogen (which yielded brown reaction products). Sections were counterstained with Mayer\'s hematoxylin solution, dehydrated and mounted. To ensure antibody specificity, negative controls included the omission of primary antibody and substitution with non-immune serum. Control slides were invariably negative for immunostaining. Positive normal brain and high grade astrocytomas (glioblastoma multiforme; World Health Organization grade IV) for CB1 and CB2 ([@b40-mmr-16-04-5285]), respectively, and human inflammatory bowel samples for TRPV channels, were also included ([@b41-mmr-16-04-5285]) as positive controls.

Two observers independently evaluated the results of immunohistochemistry in the epithelium followed by resolution of any differences by joint review. To determine the labeling index (LI; % labelled cells) for each antibody, two observers independently assessed 10 non-overlapping, random fields (total magnification, ×400) for each case and manually counted 100 epithelial cells in each field with the aid of an ocular grid. Immunopositive endothelial and stromal cells were excluded from the cell counts. Expression of proteins included in the current study was examined in adjacent (semi-serial) sections of each sample. Microphotographs were obtained using a Nikon DXM 1200C digital camera mounted on a Nikon Eclipse 80i microscope and ACT-1C software (Nikon Instruments Inc., Melville, NY, USA) was used.

### Statistical analysis

Non-parametric methods were used for statistical analysis of the results. Median comparisons were performed with Wilcoxon\'s rank-sum test (equivalent to the Mann-Whitney U test) and the Kruskal-Wallis test. Spearmans correlation was used to assess the significance of associations between LIs. P\<0.05 was considered to indicate a statistically significant difference. Statistical analyses were performed using the SPSS package (version 17.0; SPSS, Inc., Chicago, IL, USA).

Results
=======

### Immunolocalization of CB1 and CB2 cannabinoid receptors in pterygium and normal conjunctival tissue samples

Strong cytoplasmic immunoreactivity for CB1 and CB2 receptors was detected in almost every epithelial layer of 30/32 (94%) and 25/32 (78%) pterygium tissue samples, respectively. Immunostaining usually exhibited a granular pattern. Polygonal epithelial cells were strongly immunostained by CB1 and CB2 antibodies, whereas goblet cells intermingled in the superficial layer presented weak immunostaining for CB1 and strong immunostaining for CB2 ([Fig. 1](#f1-mmr-16-04-5285){ref-type="fig"}). In certain cases, CB1 immunoreactivity was also observed in the membrane of the epithelial cells. Considerable staining heterogeneity was observed among the different pterygium tissue samples included in the current study. Furthermore, variability of epithelial positive cells was also common within individual tissues ([Fig. 2](#f2-mmr-16-04-5285){ref-type="fig"}). In the pterygium stroma, scattered cells with intense CB2 immunoreactivity ([Fig. 1B](#f1-mmr-16-04-5285){ref-type="fig"}) and vascular endothelial cells with CB1 and CB2 immunoreactivity ([Fig. 2A and C](#f2-mmr-16-04-5285){ref-type="fig"}) were observed. In conjunctival epithelium, all epithelial cell layers displayed intense CB1 immunoreactivity, although the strongest immunopositivity was detected in the basal and outermost layers; a similar pattern was observed for CB2 immunoreactivity. CB1 expression was not detected in endothelial cells. By contrast, stromal scattered cells and vascular endothelium exhibited intense CB2 expression ([Fig. 1](#f1-mmr-16-04-5285){ref-type="fig"}). Immunoreactivity of p-CB1 (Ser316) demonstrated the same distribution patterns as CB1.

### Immunolocalization of transient receptor potential vanilloid channels in pterygium and normal conjunctival tissue samples

All of the epithelial layers in 96, 73 and 80% of pterygia cases, exhibited TRPV1 TRPV2 and TRPV3 cytoplasmic immunoreactivity, respectively. The epithelium of all the pterygia cases (100%) exhibited strong, predominantly nuclear, TRPV4 immunolocalization. Similarly, the conjunctival tissue samples showed cytoplasmic TRPV1, TRPV2, TRPV3 and TRPV4 expression in a large number of epithelial cells. TRPV4 nuclear immunoreactivity was also noticed in certain epithelial cells. TRPV immunopositive vascular endothelial cells were observed in the pterygium and conjunctival samples ([Fig. 3](#f3-mmr-16-04-5285){ref-type="fig"}).

### Quantitative analyses of the immunohistochemical findings

Quantitative analyses of the immunohistochemical LIs in epithelial cells revealed no significant differences based on age and gender of patients or grade of pterygium (P≥0.05). However, significant correlations were noted between the LIs for CB1 and CB2 in primary pterygia (Spearman correlation=0.522; P=0.005), but not in recurrent pterygia (Spearman correlation=0.28; P=0.6) ([Fig. 4](#f4-mmr-16-04-5285){ref-type="fig"}). Comparison of median LIs between primary and recurrent pterygia showed a significantly higher expression level of CB1 and CB2 in primary pterygia (P=0.01). LIs for CB1 in conjunctiva were significantly higher compared with primary pterygia (P=0.04) and recurrent pterygia (P=0.03). By contrast, no significant difference was identified for CB2 LIs between conjunctiva and primary pterygia (P=0.1; [Table I](#tI-mmr-16-04-5285){ref-type="table"}). Furthermore, differences for TRPV channel expression levels between pterygium (primary or recurrent) and conjunctival tissue samples were identified, although these were not significant (P\>0.05; [Table II](#tII-mmr-16-04-5285){ref-type="table"}). A significant correlation was detected between the TRPV1 and TRPV3 expression levels (Spearman correlation=0.783; P\<0.001) independently of pterygium recurrence. Finally, TRPV channel expression was significantly higher when compared with cannabinoid receptor expression in the pterygium samples (P\<0.001).

Discussion
==========

Increasing evidence reveals that cannabinoid receptors and their endogenous ligands, termed the endocannabinoid system, are involved in a variety of physiological functions of the human eye ([@b38-mmr-16-04-5285],[@b42-mmr-16-04-5285]--[@b45-mmr-16-04-5285]). Experimental data provide information regarding the functional contribution of CB1 in eliciting responses underlying wound healing in human corneal epithelial cells ([@b31-mmr-16-04-5285],[@b46-mmr-16-04-5285]). Furthermore, cannabinoid receptors are important in the maintenance of conjunctival epithelium and in ocular surface modulation of inflammation ([@b38-mmr-16-04-5285]). According to Zheng *et al* ([@b47-mmr-16-04-5285]) activation of CB1 and CB2 receptors is required for ultraviolet (UV)-induced inflammation in skin, whereas the absence of CB1/2 receptors results in reduced UV-induced skin carcinogenesis. In addition, it is known that CB1 and CB2 activation increases cell proliferation and expands the available stem cell population ([@b48-mmr-16-04-5285]). Specifically, it has been shown that anandamide inhibits differentiation of keratinocytes and this effect is mediated by epigenetic gene methylation of keratins by CB1 ([@b49-mmr-16-04-5285],[@b50-mmr-16-04-5285]). A previous study demonstrated the novel activity of cannabinoids as transcriptional repressors via epigenetic mechanisms ([@b51-mmr-16-04-5285]). In addition to this, pterygium demonstrates abundant expression of different keratins, which have been detected as conjunctival markers ([@b52-mmr-16-04-5285],[@b53-mmr-16-04-5285]). In the present study, the expression levels of CB1 and CB2 in pterygium epithelial cells was decreased as compared to conjunctiva, and the reduction was significant with regard to CB1 expression. Based on the above-mentioned data, the reduction of cannabinoid receptors in pterygium may indicate an association of these receptors with cell differentiation and provides a tool for investigating drugs that reverse possible methylation abnormalities in pterygial epithelial cells. Thus, considering the most prevalent hypothesis for the pathogenesis of pterygium (which involves UV radiation as the principal environmental factor that affects epithelial stem cells residing at the nasal limbus ([@b1-mmr-16-04-5285])), it is logical to speculate that CB1 and CB2 may be involved in the pathogenesis of pterygium. However, further investigation is required to clarify whether the decreased expression level of cannabinoid receptors in pterygium epithelium may reflect a cytoprotective mechanism against UV or promotes the deregulation of cell proliferation at the ocular surface.

Notably, CB1 was immunolocalized in the membrane of certain pterygial epithelial cells. Recent data demonstrated that the palmitoylation of Cys^415^ in helix 8 of CB1 is critical for the membrane localization of this receptor ([@b54-mmr-16-04-5285]). Previous findings highlight the regulation of CB1 by its association with membrane microdomains and consequently its coupling with G-proteins ([@b55-mmr-16-04-5285]). Furthermore, only a proportion of epithelial cells demonstrated CB1 membrane immunoreactivity. Further studies on the concept of the membrane environment of pterygial cells are necessary for decoding the regulation of cannabinoid receptors in these cells. However, the intracellular CB1 receptors located in the majority of conjunctival and pterygial epithelial cells may also be functional. Previous data indicate that the intracellular CB1 receptor mediates signal transduction by stimulating extracellular regulated kinase (ERK) phosphorylation ([@b56-mmr-16-04-5285]). CB2 cytoplasmic expression was detected in conjunctival and pterygial epithelial cells. He *et al* ([@b57-mmr-16-04-5285]) demonstrated the involvement of CB2 in cell migration via the Gi-Ras-related C3 botulinum toxin substrate 1 signaling pathway with the support of heat shock protein90 (Hsp90), which may serve as a scaffold to maintain CB2 and its signaling components proximal to the cell membrane. Using geldamycin, an inhibitor of Hsp90, the authors demonstrated that Hsp90 is important as a molecular chaperone in CB2 receptor-mediated cell signaling and actin cytoskeleton rearrangement in trabecular meshwork cells ([@b58-mmr-16-04-5285]). In our previous study ([@b59-mmr-16-04-5285]) the abundant expression of Hsp90 in pterygial epithelial cells was displayed in contrast to that in conjunctival cells. In addition, correlation analysis revealed that Hsp90 expression is significantly correlated with the expression of CB2 receptor (Spearman\'s rho=0.660; P\<0.01) in pterygium samples, but not in conjunctiva (P\>0.05). These results imply that Hsp90 may be involved in CB2 receptor signaling in the epithelium of pterygium.

Previous studies have shown that although the tissues of recurrent and primary pterygia are very similar histopathologically ([@b60-mmr-16-04-5285]), the biology of recurrent pterygia is quite different to that of primary pterygium and the prognosis is worse ([@b61-mmr-16-04-5285]). In the current study, it was immunohistochemically demonstrated that, compared with primary pterygium, cannabinoid receptor expression levels were decreased in recurrent pterygium. Notably, the expression level of CB1 was correlated with the expression of CB2 in primary pterygial epithelial cells, but not in recurrent pterygia, although the number of recurrent pterygia was particularly low in the current study and further experiments with a larger series of recurrent pterygia are required. These findings indicate the presence of different pathological mechanisms between primary and recurrent pterygia. Thus, in recurrent pterygium, there may be a loss of epithelial cells containing cannabinoid receptors and/or differentially regulated expression of these receptors in the epithelium.

TRPV channels are abundantly expressed in skin epithelial cells ([@b62-mmr-16-04-5285]). This expression has been linked to normal pain and temperature sensation ([@b36-mmr-16-04-5285]). In the current study, TRPV1, TRPV2, TRPV3 and TRPV4 wide expression was identified in pterygial and conjunctival epithelial cells based on immunohistochemical evaluation. No significant difference in TRPV channel expression was identified between pterygium and conjunctival epithelial cells although a reduction of TRPV1, TRPV2 and TRPV4 expression levels and an increased level of TRPV3 expression was detected in pterygial epithelium. Previously, Mergler *et al* ([@b39-mmr-16-04-5285]) established the functional activity of TRPV1, TRPV2 and TRPV4 channels in human conjunctival epithelial cells, which includes cell-volume control and thermosensitivity supporting conjunctival tissue homeostasis. Furthermore, functional studies in corneal epithelial cells demonstrated the involvement of TRPV3 in thermosensation and wound healing ([@b63-mmr-16-04-5285]), as well as the mediatory role of TRPV1 in pro-inflammatory cytokine secretion ([@b64-mmr-16-04-5285]). These data support the hypothesis that the expression of TRPV channels in epithelial pterygial and conjunctival cells is essential for the maintenance of epithelium homeostasis for pterygium and conjunctiva.

TRPV4 was shown with an unusual distribution profile in the nucleus of the majority of epithelial pterygial cells. Notably, a previous study demonstrated that TRPV4 is predominantly located in the nucleus of cultured neonatal ventricular myocytes; however, following hypotonic stimulation, the TRPV4 protein was translocated out of the nucleus ([@b65-mmr-16-04-5285]). Indeed, in the present study, primarily nuclear TRPV4 immunoreactivity was identified in pterygium epithelium, compared with the conjunctiva, where the TRPV4 was cytoplasmic and only identified in the nucleus in certain cells. The above findings provide evidence of the involvement of TRPV4 in additional functions, including in the nucleus of pterygial epithelial cells.

In the pterygium stroma, a variety of endothelial cells exhibited cytoplasmic immunoreactivity for CB1 and CB2. It is noteworthy that CB1 expression was not observed in conjunctival stromal vessels in the present study. These findings reveal an induction of CB1 expression in pterygium endothelial cells, which indicates a role of CB1 in pterygium angiogenesis. There is evidence for the existence of endothelial receptors, termed endothelial cannabinoid receptors, which mediate endocannabinoid-induced vasodilation ([@b66-mmr-16-04-5285]) and improve tissue oxygenation in hypoxic conditions. These endothelial receptors were proposed to act independently of CB1 and CB2 receptors. However, the presence of CB1 and CB2 receptors in pterygium vessels highlights the vascular responsiveness of pterygium to cannabinoids. It is well known that cannabinoids affect gap junctions, a critical aspect of vascular electrical and mechanical responses ([@b67-mmr-16-04-5285]). Previous data have shown that CB1 receptors located in human vascular endothelium are functionally coupled to the mitogen-activated protein kinase cascade, and activation of these protein kinase cascades by anandamide may contribute to the modulation of endothelial cell growth and proliferation ([@b68-mmr-16-04-5285]).

Additionally, TRPV channel expression was observed in pterygium and conjunctival endothelial cells. In human corneal endothelial cells, functional TRPV4 expression was reported ([@b69-mmr-16-04-5285]), and TRPV1, TRPV2 and TRPV3 activity was modulated by temperature providing an essential homeostatic mechanism of corneal endothelial function under different ambient conditions ([@b70-mmr-16-04-5285]). Furthermore, cannabinoid ligands abate the inflammatory activation of human endothelial cells, but paradoxically, TRPV1 inhibition augments inflammation in the absence of the cannabinoids ([@b71-mmr-16-04-5285]). TRPV channels are also expressed in smooth muscle and perivascular cells indicating their role in modulating vascular function, perceiving and responding to local environmental changes ([@b72-mmr-16-04-5285]). In the present study, cannabinoid receptors and TRPV channel immunoreactivity was identified in stromal cells. Thus, these results indicate that the endothelial endocannabinoid system may represent a useful tool for anti-angiogenic therapeutic strategies in pterygium.

Previous findings have established an interaction between TRPVs, particularly TRPV1 and CB1, when they are co-expressed in the same cells. Indeed, crosstalk between CB1 and TRPV1 modulates pain and inflammation in arthritis ([@b33-mmr-16-04-5285]). CB1 and TRPV1 may function as constitutively and/or continuously activated receptors via endocannabinoids for proliferation and survival of epidermal keratinocytes ([@b73-mmr-16-04-5285],[@b74-mmr-16-04-5285]) and human corneal epithelial cells ([@b46-mmr-16-04-5285]). Suppression of TRPV1-induced inflammatory responses to corneal injury by CB1 activation has been reported ([@b31-mmr-16-04-5285],[@b46-mmr-16-04-5285]).

In conclusion, in the present study, the majority of epithelial cells in conjunctiva demonstrate CB1 and TRPV1 expression co-localization based on overlapping immunostaining. Taken together, injury (e.g. endogenous ligand release, environmental stresses and/or infections) to epithelial cells activates: i) TRPV1 inducing proinflammatory cytokine and chemoattractant expression ([@b75-mmr-16-04-5285]); ii) CB1 leading to reduction of inflammation ([@b76-mmr-16-04-5285]); and iii) the protein-protein interaction between TRPV1 and CB1, which downregulates TRPV1-induced inflammation ([@b31-mmr-16-04-5285],[@b46-mmr-16-04-5285]). Thus, it appears that there is an adaptive mechanism, which sustains the epithelial protective barrier function against infection and injury in conjunctiva. However, it is likely that this balance is disturbed in pterygium epithelium due to the reduction of cannabinoid receptor expression. However, there are a proportion of cells that express CB1 (and CB2) in addition to TRPV channels in pterygium. Therefore, developing strategies to either block injury-induced TRPV1 activation or promote CB1 activation may provide novel therapeutic approaches for pterygium. Further studies may clarify how the differential expression and regulation of these receptors correlates with the severity of pterygium pathogenesis and demonstrate the effects of the cannabinoids in this type of conjunctival lesion.

![Panel depicting the cellular distribution of cannabinoid receptors, CB1 and CB2 inhuman primary pterygia. (A) Strong diffuse cytoplasmic immunoreactivity in numerous epithelial cells for CB1. (A, insert) In human conjunctiva, all epithelial cells, but predominantly epithelial cells localized in basal and suprabasal layers, demonstrate CB1 immunoreactivity. (B) Cytoplasmic CB2 immunolocalization in all epithelial layers. Note that goblet cells demonstrate strong CB2 immunopositivity. Certain cells also exhibit nuclear CB2 immunoreactivity. Furthermore, CB2 immunolocalization is distributed in the cytoplasm of scattered stromal cells. (B, insert) In human conjunctiva, strong CB2 immunoreactivity is primarily localized in basal and suprabasal layers. Strong CB2 immunoreactivity is also present in vascular endothelium and stromal cells. (C and D) Strong and moderate granular cytoplasmic immunoreactivity for CB1 and CB2, respectively, in homologous fields of immediately adjacent sections of a pterygium sample. (C, insert) Immunostaining is absent in negative controls sections. Counterstain, hematoxylin; original magnification, ×400; scale bar, 50 µm. CB1, cannabinoid receptor type 1; CB2, cannabinoid receptor type 2.](MMR-16-04-5285-g00){#f1-mmr-16-04-5285}

![Expression patterns for CB1 in human pterygia with staining patterns demonstrating heterogeneity. (A) CB1 is distributed in epithelium, stromal vessels, and a gland of a primary pterygium sample. (A, insert) Note CB1 immunolocalization predominantly in the upper layers of epithelium. (B) The membrane of epithelial cells is strongly immunostained for CB1 (arrows) in a primary pterygium sample. (C) Basal cells (oval) and vessels (arrows) in pterygium stroma are immunostained for CB1 in another primary pterygium sample. (D) Variability of CB1 immunopositive cells is detected in a recurrent pterygium sample. Counterstain, hematoxylin; original magnification, ×400; scale bar, 50 µm. CB1, cannabinoid receptor type 1; CB2, cannabinoid receptor type 2.](MMR-16-04-5285-g01){#f2-mmr-16-04-5285}

![TRPV immunolocalization in pterygium and conjunctival tissue samples. Cytoplasmic TRPV1 expression in (A) primary pterygium and (B) conjunctiva samples. Endothelial cells are TRPV1 immunopositive. (B, insert) Immunostaining is absent in negative controls sections. (C) Photomicrographs from the same recurrent pterygium sample demonstrating immunostaining heterogeneity for TRPV3 expression in (top) epithelial cells and (bottom) epithelial cells with strong TRPV3 cytoplasmic immunoexpression with wide distribution. Endothelial cells exhibit TRPV3 immonopositivity. Immunostaining was weak for CB1 (LI=5) and absent for CB2 (LI=0) cannabinoid receptors. Photomicrographs from the same primary pterygium sample displaying (D) weak TRPV2 (LI=8) and (E) predominantly nuclear TRPV4 (LI=80) immunoreactivity in epithelial cells. Note that TRPV4 expression is visible in all layers of the pterygium sample, including a few goblet cells. Vessels demonstrate TRPV2 and TRPV4 immunoreactivity. In addition, immunostaining for CB1 (LI=60) and CB2 (LI=50) cannabinoid receptors was detected. (F) TRPV4 immunostaining is localized in the cytoplasm and nucleus of basal and suprabasal epithelial cells, as well as in certain lamina propria cells in this conjunctival sample. Counterstain, hematoxylin; original magnification, ×400; scale bar, 50 µm. TRPV, transient receptor potential cation channel subfamily V member; CB1, cannabinoid receptor type 1; LI, labeling index; CB2, cannabinoid receptor type 2.](MMR-16-04-5285-g02){#f3-mmr-16-04-5285}

![Spearman correlation analysis revealed a highly significant association between CB1 and CB2 LIs in primary pterygia (r^2^=0.522; P=0.005), although not in recurrent pterygia (r^2^=0.28; P=0.6). The scatter plot graph presents the comparison of LIs for CB1 and CB2 in primary and recurrent pterygia. P\<0.05 was considered to indicate a statistically significant difference. Primary and recurrent pterygia are represented by diamond and circular symbols, respectively. CB2, cannabinoid receptor type 2; LI, labeling index; CB1, cannabinoid receptor type 1.](MMR-16-04-5285-g03){#f4-mmr-16-04-5285}

###### 

Immunohistochemical expression of CB1 and CB2 receptors in human conjunctiva and pterygium epithelium.

  Sample                     CB1 LIs mean ± SD, % (range)                                                                                           CB2 LIs mean ± SD, % (range)
  -------------------------- ---------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------
  Primary pterygia (n=27)    43.88±32.67 (0--90)^[a](#tfn2-mmr-16-04-5285){ref-type="table-fn"}^                                                    54.81±37.55 (0--100)^[b](#tfn3-mmr-16-04-5285){ref-type="table-fn"}^
  Recurrent pterygia (n=5)   7.40±7.98 (0--20)                                                                                                      8.00±10.95 (0--20)
  Normal conjunctiva (n=8)   86.66±11.54 (80--100)^[c](#tfn4-mmr-16-04-5285){ref-type="table-fn"},[d](#tfn5-mmr-16-04-5285){ref-type="table-fn"}^   90±17.32 (70--100)^[e](#tfn6-mmr-16-04-5285){ref-type="table-fn"}^

LI, the percentage of positively-labeled cells from the total number of epithelial cells counted.

P=0.01 vs. recurrent pterygia

P=0.01 vs. recurrent pterygia

P=0.04 vs. primary pterygia

P=0.03 vs. recurrent pterygia

P=0.03 vs. recurrent pterygia. CB1, cannabinoid receptor type 1; CB2, cannabinoid receptor type 2; LI, labeling index; SD, standard deviation.

###### 

Immunohistochemical expression of TRPV channels in human conjunctiva and pterygium epithelium.

  LIs mean ± standard deviation, % (range)   Pterygia (n=32)        Normal conjunctiva (n=8)
  ------------------------------------------ ---------------------- --------------------------
  TRPV1                                      84.79±22.91 (0--100)   100.00±0.00 (100--100)
  TRPV2                                      23.57±27.23 (0--100)   53.33±50.33 (0--100)
  TRPV3                                      61.00±38.64 (0--100)   33.33±27.74 (0--100)
  TRPV4                                      54.50±27.23 (10--90)   80.00±0.00 (80--80)

LI, labeling index; TRPV, transient receptor potential cation channel subfamily V member.
